ClinicalTrials.gg
RecruitingNCT04616313Updated Aug 14, 2025

Novel Pulmonary Imaging of Lung Structure and Function in E-cigarette Smokers

An observational study in E Cigarette Use, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Western University, Canada · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Vaping with a site in Canada — 6 open to participants now, 8 under way, 1 of them phase 3. Vaping · Canada.

Started
2023
with 2 others
Observational
3 of 13
3 open now
Registered
4th of 13
by date

Among the 13 studies in Vaping with a site in Canada, this one is one of 3 that started in 2023, is one of 3 observational ones, and was the 4th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

6 of the 13 studies in Vaping with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Vaping with a site in Canada, or all of them as a file.
02

Study summary

This is a longitudinal study of the long-term health impact of e-cigarette smoking on the lungs. Participants will be followed over a period of 5 years, and impacts of e-cigarette smoking on the lungs will be measured with magnetic resonance imaging (MRI) using hyperpolarized xenon-129 gas, pulmonary function tests, exercise capacity, computed tomography images and questionnaires.

Read the detailed description

This is a 5-year longitudinal study of the long-term lung health impact of e-cigarette smoking. Participants with a history of e-cigarette smoking age ≥ 16 years will be recruited from within 2 hours of London, ON through local family and tertiary care physicians, emergency departments and community and social media advertisements. Asymptomatic age and sex-matched participants who have never smoked e- or c-cigarettes will be recruited through community advertisement, media and social media. Participants must satisfy all inclusion and exclusion criteria in order to participate in the study. We will compare lung health of participants at baseline, 12 weeks, 24 weeks and 48 weeks, 3 years, 4 years and 5 years with an asymptomatic control group with no history of e-cigarette or c-cigarette use. The study will involve 6 in-person visits and 1 telephone call for a health update. All measurements will be made with at least 4 hours after the last cigarette and/or vape to provide a way to practically focus on chronic and not acute effects. Pulmonary function and imaging measurements will be made before and after bronchodilator administration.

At Visit 1, informed consent will be obtained before any study related assessments or procedures are performed. Eligibility criteria will be reviewed. Safety assessments including vital signs, pulmonary function testing, hematology, sputum sampling, exercise testing, and respiratory questionnaires will be completed.

Visit 2 will take place 12 weeks after visit 1 and will include vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, chest CT scan, exercise testing, and questionnaires.

Visit 3 will take place at 24 weeks and will involve a telephone call to update health information as well as questionnaires.

Visit 4 will take place at 48 weeks and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, hematology, blood chemistry, sputum analysis, exercise testing, and questionnaires.

Visit 5 will take place at year 3 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.

Visit 6 will take place at year 4 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.

Visit 7 will take place at year 5 and will involve vital signs, pre and post bronchodilator pulmonary function testing, pre and post bronchodilator MRI imaging, blood draw, sputum induction and analysis, exercise testing and questionnaires.

03

Conditions studied

  • E Cigarette Use

Browse trials for

Keywords

  • e-cigarette smoking
  • pulmonary function
  • Xenon-129
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  1. e-cigarette users who did not require hospitalization, nor used c-cigarettes
  2. e-cigarette users who also consumed c-cigarettes
  3. never smokers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be directly obtained from legally competent participants before any study-related assessment is performed.
  • Male and female participant age ≥16 years.
  • Participant has recently started vaping, >1 and \<5 years weekly use.
  • 70 participants will be c-cigarette never users.
  • 70 participants will be former or current c-cigarette users.
  • 10 asymptomatic age and sex-matched healthy people who have never used e- or c-cigarettes will be controls.

Exclusion criteria

Exclusion Criteria:

  • Participants with for undergoing an MRI such as participants with MRI-sensitive implants, tattoos with MRI-sensitive dye and severe claustrophobia.
  • Participant is, in the opinion of the investigator, mentally or legally incapacitated, preventing from being obtained, or cannot read or understand written material.
  • Participant unable to perform spirometry or plethysmography maneuvers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • c-cigarette never users

    Includes 70 participants who are e-cigarette users who have never smoked combustible cigarettes.

    Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires

  • former or current c-cigarette users

    Includes 70 participants who are e-cigarette users who are also former or current combustible cigarette smokers.

    Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires

  • never smokers

    Includes 10 participants who have never smoked e-cigarettes or combustible cigarettes.

    Diagnostic Test: Hyperpolarized Xenon-129 MRI of the lungs · Diagnostic Test: Computed Tomography (CT) · Diagnostic Test: Pulmonary Function Tests (PFT) · Diagnostic Test: Cardiopulmonary exercise testing (CPET) · Diagnostic Test: Sputum analysis · Diagnostic Test: Blood analysis · Other: Questionnaires

Interventions

  • Diagnostic testHyperpolarized Xenon-129 MRI of the lungs

    Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

    Also known as: 129Xe MRI

  • Diagnostic testComputed Tomography (CT)

    Participants will undergo a CT scan of the thoracic cavity

    Also known as: CT

  • Diagnostic testPulmonary Function Tests (PFT)

    Participants will have their lung function evaluated using PFT

    Also known as: PFT

  • Diagnostic testCardiopulmonary exercise testing (CPET)

    Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity

    Also known as: CPET

  • Diagnostic testSputum analysis

    Participants will provide a sputum sample that will be analysed for eosinophils

  • Diagnostic testBlood analysis

    Participants will have their blood drawn and analysed for eosinophil count.

  • OtherQuestionnaires

    Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.

06

What researchers measure

Primary outcomes

  1. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report pulmonary imaging abnormalities.

    Measured using 129-Xe MRI

    Time frame: 12 weeks following enrollment

  2. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report pulmonary imaging abnormalities.

    Measured using computed tomography imaging

    Time frame: 12 weeks following enrollment

  3. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FEV1.

    Measured using forced expiratory volume in one second (FEV1)

    Time frame: 12 weeks following enrollment

  4. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FVC.

    Measured using forced vital capacity (FVC)

    Time frame: 12 weeks following enrollment

  5. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by TLC.

    Measured using total lung capacity (TLC)

    Time frame: 12 weeks following enrollment

  6. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FRC.

    Measured using functional residual capacity (FRC)

    Time frame: 12 weeks following enrollment

  7. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by RV.

    Measured using residual volume (RV)

    Time frame: 12 weeks following enrollment

  8. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FOT.

    Measured using forced oscillation technique (FOT)

    Time frame: 12 weeks following enrollment

  9. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by LCI.

    Measured using lung clearance index (LCI)

    Time frame: 12 weeks following enrollment

  10. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by FeNO.

    Measured using Fractional Exhaled Nitric Oxide (FeNO).

    Time frame: 12 weeks following enrollment

  11. Determine if e-cigarette users who did not require hospitalization, nor used c-cigarettes report respiratory symptoms or abnormal pulmonary function measured by exercise capacity

    Exercise capacity measured by cardio-pulmonary exercise testing (CPET)

    Time frame: 12 weeks following enrollment

Secondary outcomes

  1. Differences in airways between e-cigarette-only smokers and both e-cigarette and c-cigarette smokers.

    Measured using 129-Xe MRI

    Time frame: 5 years

  2. Differences in airways between e-cigarette-only smokers and never smokers.

    Measured using 129-Xe MRI

    Time frame: 5 years

  3. Differences in parenchyma between e-cigarette-only smokers and both e-cigarette and c-cigarette smokers.

    Measured using 129-Xe MRI

    Time frame: 5 years

  4. Differences in parenchyma between e-cigarette-only smokers and never smokers.

    Measured using 129-Xe MRI

    Time frame: 5 years

  5. Changes in airways of e-cigarette smokers over time.

    Measured using Xenon-129 (129-Xe) MRI

    Time frame: 5 years

  6. Changes in parenchyma of e-cigarette smokers over time.

    Measured using Xenon-129 (129-Xe) MRI

    Time frame: 5 years

  7. Changes in lung function of e-cigarette smokers over time as measured by FEV1.

    Measured using forced expiratory volume in one second (FEV1).

    Time frame: 5 years

  8. Changes in lung function of e-cigarette smokers over time as measured by FVC.

    Measured using forced vital capacity (FVC)

    Time frame: 5 years

  9. Changes in lung function of e-cigarette smokers over time as measured by TLC.

    Measured using total lung capacity (TLC)

    Time frame: 5 years

  10. Changes in lung function of e-cigarette smokers over time as measured by FRC.

    Measured using functional residual capacity (FRC)

    Time frame: 5 years

  11. Changes in lung function of e-cigarette smokers over time as measured by RV.

    Measured using residual volume (RV)

    Time frame: 5 years

  12. Changes in lung function of e-cigarette smokers over time as measured by FOT.

    Measured using forced oscillation technique (FOT).

    Time frame: 5 years

  13. Changes in lung function of e-cigarette smokers over time as measured by LCI.

    Measured using lung clearance index (LCI)

    Time frame: 5 years

  14. Changes in lung function of e-cigarette smokers over time as measured by FeNO.

    Measured using Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: 5 years

  15. Changes in lung function of e-cigarette smokers over time as measured by exercise capacity.

    Exercise capacity measured by cardio-pulmonary exercise testing (CPET)

    Time frame: 5 years

  16. Changes in lung health of e-cigarette smokers over time as measured by the mMRC dyspnea scale questionnaire.

    Measured using the modified medical research council (mMRC) dyspnea scale

    Time frame: 5 years

  17. Changes in lung health of e-cigarette smokers over time as measured by SGRQ.

    Measured using the St. George's respiratory questionnaire (SGRQ)

    Time frame: 5 years

  18. Changes in lung health of e-cigarette smokers over time as measured by CAT.

    Measured using the COPD assessment test (CAT)

    Time frame: 5 years

  19. Changes in lung health of e-cigarette smokers over time as measured by IPAQ.

    Measured using the International Physical Activity Questionnaire (IPAQ).

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre
    London, Ontario N6A 5B7, Canada
    Recruiting
08

References and documents

Publications

  • Hua M, Alfi M, Talbot P. Health-related effects reported by electronic cigarette users in online forums. J Med Internet Res. 2013 Apr 8;15(4):e59. doi: 10.2196/jmir.2324. PubMed 23567935 ↗
  • Wang MP, Ho SY, Leung LT, Lam TH. Electronic Cigarette Use and Respiratory Symptoms in Chinese Adolescents in Hong Kong. JAMA Pediatr. 2016 Jan;170(1):89-91. doi: 10.1001/jamapediatrics.2015.3024. No abstract available. PubMed 26551991 ↗
  • McConnell R, Barrington-Trimis JL, Wang K, Urman R, Hong H, Unger J, Samet J, Leventhal A, Berhane K. Electronic Cigarette Use and Respiratory Symptoms in Adolescents. Am J Respir Crit Care Med. 2017 Apr 15;195(8):1043-1049. doi: 10.1164/rccm.201604-0804OC. PubMed 27806211 ↗
  • Cho JH, Paik SY. Association between Electronic Cigarette Use and Asthma among High School Students in South Korea. PLoS One. 2016 Mar 4;11(3):e0151022. doi: 10.1371/journal.pone.0151022. eCollection 2016. PubMed 26942764 ↗
  • Schweitzer RJ, Wills TA, Tam E, Pagano I, Choi K. E-cigarette use and asthma in a multiethnic sample of adolescents. Prev Med. 2017 Dec;105:226-231. doi: 10.1016/j.ypmed.2017.09.023. Epub 2017 Sep 28. PubMed 28964850 ↗
  • Layden JE, Ghinai I, Pray I, Kimball A, Layer M, Tenforde MW, Navon L, Hoots B, Salvatore PP, Elderbrook M, Haupt T, Kanne J, Patel MT, Saathoff-Huber L, King BA, Schier JG, Mikosz CA, Meiman J. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N Engl J Med. 2020 Mar 5;382(10):903-916. doi: 10.1056/NEJMoa1911614. Epub 2019 Sep 6. PubMed 31491072 ↗
  • Henry TS, Kanne JP, Kligerman SJ. Imaging of Vaping-Associated Lung Disease. N Engl J Med. 2019 Oct 10;381(15):1486-1487. doi: 10.1056/NEJMc1911995. Epub 2019 Sep 6. No abstract available. PubMed 31491070 ↗
  • Maddock SD, Cirulis MM, Callahan SJ, Keenan LM, Pirozzi CS, Raman SM, Aberegg SK. Pulmonary Lipid-Laden Macrophages and Vaping. N Engl J Med. 2019 Oct 10;381(15):1488-1489. doi: 10.1056/NEJMc1912038. Epub 2019 Sep 6. No abstract available. PubMed 31491073 ↗
  • Davidson K, Brancato A, Heetderks P, Mansour W, Matheis E, Nario M, Rajagopalan S, Underhill B, Wininger J, Fox D. Outbreak of Electronic-Cigarette-Associated Acute Lipoid Pneumonia - North Carolina, July-August 2019. MMWR Morb Mortal Wkly Rep. 2019 Sep 13;68(36):784-786. doi: 10.15585/mmwr.mm6836e1. PubMed 31513559 ↗
  • Landman ST, Dhaliwal I, Mackenzie CA, Martinu T, Steel A, Bosma KJ. Life-threatening bronchiolitis related to electronic cigarette use in a Canadian youth. CMAJ. 2019 Dec 2;191(48):E1321-E1331. doi: 10.1503/cmaj.191402. Epub 2019 Nov 20. PubMed 31753841 ↗
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. PubMed 16055882 ↗
  • Oostveen E, MacLeod D, Lorino H, Farre R, Hantos Z, Desager K, Marchal F; ERS Task Force on Respiratory Impedance Measurements. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J. 2003 Dec;22(6):1026-41. doi: 10.1183/09031936.03.00089403. PubMed 14680096 ↗
  • Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated segmentation. Acad Radiol. 2012 Feb;19(2):141-52. doi: 10.1016/j.acra.2011.10.007. Epub 2011 Nov 21. PubMed 22104288 ↗
  • Owrangi AM, Etemad-Rezai R, McCormack DG, Cunningham IA, Parraga G. Computed tomography density histogram analysis to evaluate pulmonary emphysema in ex-smokers. Acad Radiol. 2013 May;20(5):537-45. doi: 10.1016/j.acra.2012.11.010. PubMed 23570935 ↗
  • Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17. doi: 10.1164/ajrccm.154.2.8756799. PubMed 8756799 ↗
  • McGavin CR, Artvinli M, Naoe H, McHardy GJ. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978 Jul 22;2(6132):241-3. doi: 10.1136/bmj.2.6132.241. PubMed 678885 ↗
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. PubMed 19720809 ↗
  • Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321-7. doi: 10.1164/ajrccm/145.6.1321. PubMed 1595997 ↗
  • Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. doi: 10.1249/01.MSS.0000078924.61453.FB. PubMed 12900694 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.

Of 32 observational studies under Vaping, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 46. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2020
First posted
Nov 4, 2020
StartActual
Jan 17, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04616313
Collaborators
London Health Sciences Centre
Responsible party
Dr. Grace Parraga (PhD, Scientist. Robarts Research Institute, Western University, Canada) — Principal investigator
First posted
Nov 4, 2020
Start date
Jan 17, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 14, 2025

Study contacts

Grace E Parraga, PhD
Contact
gparraga@robarts.ca
519-931-5265
Angela Wilson, RRT
Contact
awilson@robarts.ca
519-931-5777 ext. 24197
Grace E Parraga
principal investigator · Western University - Robarts Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion